These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26669880)

  • 1. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
    Williet N; Paul S; Peyrin-Biroulet L; Roblin X
    Dig Dis Sci; 2016 Apr; 61(4):990-5. PubMed ID: 26669880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent.
    Polakovicova V; Kadleckova B; Lucenicova J; Otottova K; Kinova S; Mikus P; Zelinkova Z
    Dig Liver Dis; 2019 Aug; 51(8):1112-1116. PubMed ID: 31147215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine Metabolism in the Era of Combotherapy.
    Roblin X; Williet N; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2016 Jun; 22(6):1496-501. PubMed ID: 26978723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
    Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
    Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.
    Moore C; Corbett G; Moss AC
    J Crohns Colitis; 2016 May; 10(5):619-25. PubMed ID: 26763722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment.
    Larsen L; Jess T; Drewes AM; Dige A; Fallingborg J; Jacobsen BA; Aagaard B; Agnholt J
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):964-967. PubMed ID: 31094854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.